Find Cefepime manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Maxipime, 88040-23-7, Cefepima, Cefepimum [latin], Cefepima [spanish], Cefepimum
Molecular Formula
C19H24N6O5S2
Molecular Weight
480.6  g/mol
InChI Key
HVFLCNVBZFFHBT-ZKDACBOMSA-N
FDA UNII
807PW4VQE3

Cefepime
A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.
Cefepime is a Cephalosporin Antibacterial.
1 2D Structure

Cefepime

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
2.1.2 InChI
InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
2.1.3 InChI Key
HVFLCNVBZFFHBT-ZKDACBOMSA-N
2.1.4 Canonical SMILES
C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-]
2.1.5 Isomeric SMILES
C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
2.2 Other Identifiers
2.2.1 UNII
807PW4VQE3
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Axpim

2. Bmy 28142

3. Bmy-28142

4. Bmy28142

5. Cefepim

6. Cefepime Hydrochloride

7. Maxipime

8. Quadrocef

2.3.2 Depositor-Supplied Synonyms

1. Maxipime

2. 88040-23-7

3. Cefepima

4. Cefepimum [latin]

5. Cefepima [spanish]

6. Cefepimum

7. Bmy-28142

8. Cfpm

9. Axepim

10. (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

11. 807pw4vqe3

12. 1-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium Hydroxide, Inner Salt, 7(sup 2)-(z)-(o-methyloxime)

13. Vnrx-5022

14. Chebi:478164

15. J01de01

16. Bmy 28142

17. (6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

18. Cefepime (usan/inn)

19. Unii-807pw4vqe3

20. Cefepime [usan:inn:ban]

21. Cefepime, Antibiotic For Culture Media Use Only

22. Cefepime [usan]

23. Cefepime [inn]

24. Cefepime [mi]

25. Cefepime [vandf]

26. Cefepime [who-dd]

27. Chembl186

28. Schembl65720

29. Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, Hydroxide, Inner Salt, (6r-(6alpha,7beta(z)))-

30. Dtxsid70873208

31. Bcpp000292

32. Hms2089m18

33. Hy-b0692

34. Bdbm50350470

35. Akos015850865

36. Akos016014147

37. Bcp9000504

38. Db01413

39. 7beta-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate

40. As-76125

41. Cs-0009590

42. C-2468

43. C08111

44. D02376

45. Ab01275446-01

46. Q27294816

47. 1-{[(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium

48. Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, Hydroxide, Inner Salt, (6r-(6.alpha.,7.beta.(z)))-

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 480.6 g/mol
Molecular Formula C19H24N6O5S2
XLogP3-0.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count6
Exact Mass480.12496023 g/mol
Monoisotopic Mass480.12496023 g/mol
Topological Polar Surface Area204 Ų
Heavy Atom Count32
Formal Charge0
Complexity869
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameMaxipime
PubMed HealthCefepime (Injection)
Drug ClassesAntibiotic
Drug LabelMAXIPIME (cefepime hydrochloride, USP) is a semi-synthetic, broad spectrum, cephalosporin antibiotic for parenteral administration. The chemical name is 1-[[(6R,7R)-7-[2-(2-amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0] o...
Active IngredientCefepime hydrochloride
Dosage FormInjectable
RouteInjection
Strengtheq 2gm base/vial; eq 500mg base/vial; eq 1gm base/vial
Market StatusPrescription
CompanyHospira

2 of 2  
Drug NameMaxipime
PubMed HealthCefepime (Injection)
Drug ClassesAntibiotic
Drug LabelMAXIPIME (cefepime hydrochloride, USP) is a semi-synthetic, broad spectrum, cephalosporin antibiotic for parenteral administration. The chemical name is 1-[[(6R,7R)-7-[2-(2-amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0] o...
Active IngredientCefepime hydrochloride
Dosage FormInjectable
RouteInjection
Strengtheq 2gm base/vial; eq 500mg base/vial; eq 1gm base/vial
Market StatusPrescription
CompanyHospira

4.2 Drug Indication

For the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterobacteriaceae, and multiple drug resistant Streptococcus pneumoniae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected


5.2 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
CEFEPIME
5.3.2 FDA UNII
807PW4VQE3
5.3.3 Pharmacological Classes
Cephalosporins [CS]; Cephalosporin Antibacterial [EPC]
5.4 ATC Code

J - Antiinfectives for systemic use

J01 - Antibacterials for systemic use

J01D - Other beta-lactam antibacterials

J01DE - Fourth-generation cephalosporins

J01DE01 - Cefepime


5.5 Absorption, Distribution and Excretion

Absorption

The absolute bioavailability of cefepime after an IM dose of 50 mg/kg was 82.3 (±15)% in eight patients.


Route of Elimination

Elimination of cefepime is principally via renal excretion with an average (SD) half-life of 2 (0.3) hours and total body clearance of 120 (8) mL/min in healthy volunteers. Cefepime is excreted in human milk.


Volume of Distribution

18.0 2.0 L

0.3 0.1 L/kg [Pediatric]


Clearance

120 mL/min [Healthy adult male receiving a single 30-minute IV infusions of cefepime]

3.3 +/-1.0 mL/min/kg [Petriatic patients (2 months 11 years of age) receiving a single IV dose]


5.6 Metabolism/Metabolites

Hepatic. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide).


5.7 Biological Half-Life

2.0 (± 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (± 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (± 2.0) hours.


5.8 Mechanism of Action

Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 88040-23-7 / Cefepime API manufacturers, exporters & distributors?

Cefepime manufacturers, exporters & distributors 1

64

PharmaCompass offers a list of Cefepime API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cefepime manufacturer or Cefepime supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefepime manufacturer or Cefepime supplier.

PharmaCompass also assists you with knowing the Cefepime API Price utilized in the formulation of products. Cefepime API Price is not always fixed or binding as the Cefepime Price is obtained through a variety of data sources. The Cefepime Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Cefepime

Synonyms

Maxipime, 88040-23-7, Cefepima, Cefepimum [latin], Cefepima [spanish], Cefepimum

Cas Number

88040-23-7

Unique Ingredient Identifier (UNII)

807PW4VQE3

About Cefepime

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Cefepime [USAN:INN] Manufacturers

A Cefepime [USAN:INN] manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefepime [USAN:INN], including repackagers and relabelers. The FDA regulates Cefepime [USAN:INN] manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefepime [USAN:INN] API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Cefepime [USAN:INN] manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Cefepime [USAN:INN] Suppliers

A Cefepime [USAN:INN] supplier is an individual or a company that provides Cefepime [USAN:INN] active pharmaceutical ingredient (API) or Cefepime [USAN:INN] finished formulations upon request. The Cefepime [USAN:INN] suppliers may include Cefepime [USAN:INN] API manufacturers, exporters, distributors and traders.

click here to find a list of Cefepime [USAN:INN] suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cefepime [USAN:INN] USDMF

A Cefepime [USAN:INN] DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefepime [USAN:INN] active pharmaceutical ingredient (API) in detail. Different forms of Cefepime [USAN:INN] DMFs exist exist since differing nations have different regulations, such as Cefepime [USAN:INN] USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Cefepime [USAN:INN] DMF submitted to regulatory agencies in the US is known as a USDMF. Cefepime [USAN:INN] USDMF includes data on Cefepime [USAN:INN]'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefepime [USAN:INN] USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Cefepime [USAN:INN] suppliers with USDMF on PharmaCompass.

Cefepime [USAN:INN] CEP

A Cefepime [USAN:INN] CEP of the European Pharmacopoeia monograph is often referred to as a Cefepime [USAN:INN] Certificate of Suitability (COS). The purpose of a Cefepime [USAN:INN] CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cefepime [USAN:INN] EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cefepime [USAN:INN] to their clients by showing that a Cefepime [USAN:INN] CEP has been issued for it. The manufacturer submits a Cefepime [USAN:INN] CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cefepime [USAN:INN] CEP holder for the record. Additionally, the data presented in the Cefepime [USAN:INN] CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cefepime [USAN:INN] DMF.

A Cefepime [USAN:INN] CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cefepime [USAN:INN] CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Cefepime [USAN:INN] suppliers with CEP (COS) on PharmaCompass.

Cefepime [USAN:INN] WC

A Cefepime [USAN:INN] written confirmation (Cefepime [USAN:INN] WC) is an official document issued by a regulatory agency to a Cefepime [USAN:INN] manufacturer, verifying that the manufacturing facility of a Cefepime [USAN:INN] active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cefepime [USAN:INN] APIs or Cefepime [USAN:INN] finished pharmaceutical products to another nation, regulatory agencies frequently require a Cefepime [USAN:INN] WC (written confirmation) as part of the regulatory process.

click here to find a list of Cefepime [USAN:INN] suppliers with Written Confirmation (WC) on PharmaCompass.

Cefepime [USAN:INN] NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cefepime [USAN:INN] as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Cefepime [USAN:INN] API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Cefepime [USAN:INN] as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Cefepime [USAN:INN] and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cefepime [USAN:INN] NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Cefepime [USAN:INN] suppliers with NDC on PharmaCompass.

Cefepime [USAN:INN] GMP

Cefepime [USAN:INN] Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cefepime [USAN:INN] GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cefepime [USAN:INN] GMP manufacturer or Cefepime [USAN:INN] GMP API supplier for your needs.

Cefepime [USAN:INN] CoA

A Cefepime [USAN:INN] CoA (Certificate of Analysis) is a formal document that attests to Cefepime [USAN:INN]'s compliance with Cefepime [USAN:INN] specifications and serves as a tool for batch-level quality control.

Cefepime [USAN:INN] CoA mostly includes findings from lab analyses of a specific batch. For each Cefepime [USAN:INN] CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cefepime [USAN:INN] may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefepime [USAN:INN] EP), Cefepime [USAN:INN] JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefepime [USAN:INN] USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty